---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-000517"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T12:32:02.996244+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares

## Summary
- Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.
- Oramed receives 2.5M of 5M free-trading Scilex shares from SCLX JV as consideration for the deferral.
- Term sheet contemplates 4% royalty on global net sales of Gloperba and Elyxyb (ex-Canada) for 10 years.
- Scilex must extend $25M promissory note maturity to Dec 31, 2025; Oramed has discretion on terms.
- $1.11M cash paid to noteholders for portion of amortization and make-whole interest.

## SEC filing metadata
- accession: 0001213900-25-000517
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025000517/0001213900-25-000517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025000517/ea0226709-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-000517
- JSON: https://secwatch.observer/filing/0001213900-25-000517.json
- Plain text: https://secwatch.observer/filing/0001213900-25-000517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.